Igor Klepikov*

MD, Professor, Retired, Renton, WA, USA

*Corresponding Author: Igor Klepikov, MD, Professor, Retired, Renton, WA, USA.p>

Received: November 04, 2022; Published: January 24, 2023

Acute pneumonia (AP) is one of the oldest nosologies known to medicine, which for many centuries has rightfully been attributed to severe diseases with high mortality. For most of its history, the search for ways to help patients with AP has been conducted empirically, but this disease has never been included in the category of contagious and did not pose a danger to others.

References

1. Heffron R. “Pneumonia, with special reference to pneumococcus lobar pneumonia”. Cambridge: Harvard University Press (1939).
2. Small JT. “A short history of the pneumococcus with special reference to lobar pneumonia”. Edinburgh Medical Journal 3 (1948): 129-141.
3. Musher DM., et al. “Evolving understanding of the causes of pneumonia in adults, with special attention to the role of pneumococcus”. Clinical Infectious Diseases10 (2017): 1736-1744.
4. Shoar S., et al. “Etiology of community-acquired pneumonia in adults: a systematic review”. Pneumonia 12 (2020): 11.
5. Cilloniz C., et al. “Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns”. International Journal of Molecular Sciences12 (2016): 2120.
6. “Revised global burden of disease 2002 estimates” (2004).
7. Rudan I., et al. “Epidemiology and etiology of childhood pneumonia”. Bulletin of the World Health Organization 86 (2008): 408-416.
8. Ruuskanen O., et al. “Viral pneumonia". Lancet9773 (2011): 1264-1275.
10. J P Metlay., et al. “Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America”. American Journal of Respiratory and Critical Care Medicine7 (2019): e45-e67.
11. Paula Peyrani., et al. “The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance”. Expert Review of Respiratory Medicine2 (2019): 139-152.
12. Rawson TM., et al. “Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing”. Clinical Infectious Diseases (2020): ciaa 530.
13. B Beovic., et al. “Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey”. Journal of Antimicrobial Chemotherapy, dkaa326 (2020).
14. Ocampo-Torres Moisés., et al. “Characterization of Mortality by Covid-19 in a Health System in Central Mexico”. EC Pulmonology and Respiratory Medicine12 (2020): 20-22.
15. B O’Kelly., et al. “Antibiotic prescribing patterns in patients hospitalized with COVID-19: lessons from the first wave”. JAC-Antimicrobial Resistance2 (2021): dlab085.
16. Puzniak L., et al. “A multicenter analysis of the clinical microbiology and antimicrobial usage in hospitalized patients in the US with or without COVID-19”. BMC Infectious Diseases 21 (2021): 227.
17. BD Huttner., et al. “COVID-19: don't neglect antimicrobial stewardship principles!” Clinical Microbiology and Infection 7 (2020): 808-810.
18. Lipman M., et al. “SARS-CoV-2 pandemic: clinical picture of COVID-19 and implications for research”. Thorax 75 (2020): 614-616.
20. Klepikov I. “How many pneumonias exist in nature?”. European Journal of Clinical Microbiology and Infectious Diseases (2020).
21. Ponsford MJ., et al. “Burden of nosocomial COVID-19 in Wales: results from a multicentre retrospective observational study of 2508 hospitalised adults”. Published Online (2021).
22. C Heneghan., et al. “Differentiating viral from bacterial pneumonia. April 8, 2020. The Centre for Evidence-Based Medicine. Evidence Service to support the COVID-19 response”. University of Oxford (2020).
23. Kamat IS., et al. “Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A Systematic Review and Meta-analysis”. Clinical Infectious Diseases3 (2020): 538-542.
24. Kim D., et al. “Rates of co-infection between SARS-CoV-2 and other respiratory pathogens”. JAMA 323 (2020): 2085-2086.
25. Merad M and Martin JC. “Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages”. Nature Reviews Immunology 20 (2020): 355-362.
26. Z Wu and JM McGoogan. “Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention”. JAMA13 (2020): 1239-1242.
27. Zhou B., et al. “COVID‐19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations”. Journal of Medical Virology (2021): 1-11.
28. Grasselli G., et al. “Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy”. JAMA (2020).
29. S Richardson., et al. “Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area”. Published online April 22 (2020).
30. Renato Seligman and Beatriz Graeff Santos Seligman (2020). “Pandemic in the 21st Century. The Challenge of COVID-19”. EC Pulmonology and Respiratory Medicine8 (2020): 30-31.
31. Gupta S., et al. “Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19”. JAMA Internal Medicine11 (2020): 1436-1446.
32. R E Leiter. “Reentry”. NEJM, October 14, 2020 (2020).
33. J N Rosenquist. “The Stress of Bayesian Medicine — Uncomfortable Uncertainty in the Face of Covid-19”. NEJM 384 (2021): 7-9.
34. Lai J., et al. “Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019.” JAMA Network Open3 (2019): e203976-e203976.
35. A Liapikou., et al. “The management of severe community acquired pneumonia in the ICU. June 2014”. Expert Review of Respiratory Medicine3 (2014): 293-303.
36. J W Kim., et al. “The Prognostic Factors of Pneumonia with Septic Shock in Patients Presenting to the Emergency Department”. Korean Journal of Critical Care Medicine4 (2015): 258-264.
37. P Jason., et al. “Severe community-acquired pneumonia: timely management measures in the first 24 hours”. Critical Care 20 (2016): 237.
38. A Vidal and L Santos. “Comorbidities impact on the prognosis of severe acute community-acquired pneumonia”. Porto Biomedical Journal6 (2017): 247-346.
39. A Ceccato and A Torres. “Sepsis and community-acquired pneumonia”. Annals of Research Hospitals 2 (2018): 7.
40. Jeremiah SS., et al. “Potent antiviral effect of silver nanoparticles on SARS-CoV-2”. Biochemical and Biophysical Research Communications 1 (2020): 195-200.
41. Reznikov L R., et al. “Identification of antiviral antihistamines for COVID-19 repurposing”. Biochemical and Biophysical Research Communications 538 (2021): 173-179.
42. Budak GG., et al. “Preclinical toxicity test results of a new antiviral-immune-modulator compound consisting of flavonoid molecules (COVID-19 clinical trial preliminary data)”. Exploration of Medicine 3 (2022): 1-21.
44. Easley D. “Networks, Crowds and Markets: Reasoning about a Highly Connected World”. Cambridge University Press. Chapter 16 (2010).
45. I Klepikov. “The Didactics of Acute Lung Inflammation”. Cambridge Scholars Publishing, (2022): 320.

Citation

Citation: Igor Klepikov. “Modern Didactic Problems of Acute Inflammation of Lung Tissue”.Acta Scientific Medical Sciences 7.2 (2023): 139-145.

Copyright

Copyright: © 2022 Igor Klepikov. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.